Navigation Links
Genzyme Reports Strong Second-Quarter Growth
Date:7/23/2008

metables therefore and the impact of such approvals on the company; its plans and estimated timetables for new and next- generation product filings, approvals and launches, including for Mozobil, Genz-112638, and Synvisc-ONE, its estimates of the sales potential of Clolar and Mozobil; its anticipated growth drivers for certain products and businesses, including Genetics; and its expectations for Renvela formulary access. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those forecasted. These risks and uncertainties include, among others: Genzyme's ability to obtain and maintain regulatory approvals for products and manufacturing facilities, including Myozyme produced at the 2000L scale in the US and at the 4000L scale in Europe and the timing of receipt of such approvals; Genzyme's ability to successfully complete preclinical and clinical development of its products and product candidates, including Mozobil and Genz-112638; Genzyme's ability to expand the use of current and next-generation products in existing and new indications, including Renvela, Clolar and Synvisc-ONE; Genzyme's ability to manufacture its products, including Thymoglobulin and its LSD therapies in a timely and cost effective manner and in sufficient quantities to meet demand; and the risks and uncertainties described in Genzyme's SEC reports filed under the Securities Exchange Act of 1934, including the factors discussed under the caption "Risk Factors" in Genzyme's 2008 Quarterly Report on Form 10-Q for the quarter ended March 31, 2008. Genzyme cautions investors not to place substantial reliance on the forward-looking statements contained in this press release. These statements speak only as of today's date and Genzyme undertakes no obligation to update or revise the statements.

Genzyme(R), Myozyme(R), Fabrazyme(R), Cerezyme(R), Thyrogen(R), Renagel(R), Renvela(R), Thymoglobulin(R), Synvisc(R), Campath(R) and Clolar(R) are
'/>"/>

SOURCE Genzyme Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
2. Genzyme Begins Major Expansion of Boston Manufacturing Facility
3. Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share
4. Genzyme Receives Approval to Market Elaprase(R) in Japan
5. Genzyme Recognized by Scientists as a Top Employer
6. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
7. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
8. Genzyme Launches Cholestagel(R) in Europe
9. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
10. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
11. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... The report “Service Quality Management ... Product Type & Provider Type - Global ... and segments the market with an in-depth ... Browse 152 market data tables, 19 figures ... on “Service Quality Management (SQM) and Telco ...
(Date:12/24/2014)... SILVER SPRING, Md. , Dec. 24, 2014 ... ) announced today that Medtronic, Inc. (NYSE: ... application to the U.S. Food and Drug Administration ... II implantable drug infusion system (including a ... Remodulin ® (treprostinil) Injection delivered intravenously to ...
(Date:12/24/2014)... NEW YORK , Dec. 24, 2014 /PRNewswire/ ... company advancing patient care in critical areas, announced the ... of common stock, and warrants to purchase up to ... offering price of $4.00 per share and $.01 per ... of $5.00, are exercisable immediately, and expire 5 years ...
(Date:12/24/2014)... , Dec. 24, 2014  Vermillion, Inc. (Nasdaq: ... gynecologic disease, announced today that the Company closed ... Oracle Investment Management, Jack W. Schuler , ... proceeds were $10.5 million, before offering expenses.  The ... general corporate purposes. Under the terms ...
Breaking Biology Technology:Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3
... PRA, a leading Clinical Research Organization, continues our expansion ... of an office in Singapore. The office will serve ... strengthening the quality and timeliness of our deliverables to ... the heart of the city-state, will provide monitoring, project ...
... PARK, Calif., Feb. 23, 2012 Telome Health, Inc.™, ... telomere biology in human health, has announced that co-founder and ... Year by Silicon Valley Business Journal. ... award, especially coming from the heart of innovation, Silicon Valley, ...
... Calif., Feb. 21, 2012 Keck Graduate Institute (KGI) ... (CGS) and the Alfred P. Sloan Foundation to administer ... part of establishing and maintaining high quality standards for ... honored to be selected and we look forward to ...
Cached Biology Technology:PRA Opens Office in Singapore 2Telome Health Co-founder and Nobel Laureate Elizabeth Blackburn Awarded Innovator of the Year 2KGI Selected to Administer PSM Affiliation Process 2
(Date:12/24/2014)... NEW YORK , Dec. 23, 2014  Since its ... has helped thousands of people to eliminate the pain ... replacing the antiquated system with their own biometrics fused ... to remember usernames and passwords, Hoyos Labs , ... identity, announced today that it is offering the app ...
(Date:12/22/2014)... SHELTON, Conn. , Dec. 22, 2014  NXT-ID, ... or the "Company"), a biometric authentication company focused on ... famous pickpocket, entertainer and security consultant, Apollo Robbins ... Wocket™ biometric smart wallet.  Apollo ... 6th and 7 th , 2015, demonstrating some of ...
(Date:12/22/2014)... Dec. 22, 2014 Research and Markets ... the addition of the "The Global ... their offering. ... an overview of the global digital media ... control and monitor piracy by securely and ...
Breaking Biology News(10 mins):1U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4The Global Watermarking and Fingerprinting Markets 2
... Atlantis rockets into space later this week, it will ... study how their genetic responses and their ability to ... part of the STS-115 space shuttle mission scheduled for ... Salmonella typhimurium, Pseudomonas aeruginosa and Candida albicans -- that ...
... Virginia Health System have shown for the first time ... muscle cells can reverse myotonic dystrophy, the most common ... 40,000 people in the United States have myotonic muscular ... wasting of the muscles, irregular heartbeat, cataracts and insulin ...
... the Rubeho Mountains in Tanzania revealed over 160 ... eleven endemic species--according to an article published in ... findings elevate the importance of protecting this biologically-rich ... range from destructive activities underway such as clear-cutting ...
Cached Biology News:Microscopic passengers to hitch ride on space shuttle 2Microscopic passengers to hitch ride on space shuttle 3Toxic molecule may cause most common type of muscular dystrophy 2First surveys of Tanzanian mountains reveal 160+ animal species, including new & endemic 2
...
... The ideal modular cleanroom for biological ... that require cleanliness (to Class 10/ISO ... precision-joined to create ultra-smooth surfaces that ... disinfect. One-inch radius corners simplify cleaning. ...
This free-standing work station safely ventilates fumes upwards, away from the work surface. Optional Exhaust Purification System features bonded charcoal filters that remove organic chemical vapors ...
... Analysis Note: Protein determined by ... 3.2 M (NH 4 ) ... 7.0 Preparation Note: Affinity purified ... suspension • Additives: MgCl 2 ...
Biology Products: